HRMY - Company ID 0001802665
The table below shows Harmony Biosciences Holdings, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $215.39M | $239.46M | $200.49M | $184.73M | $186.04M | $172.81M |
| Cost of revenue | $44.51M | $59.65M | $38.15M | $31.99M | $42.78M | $32.14M |
| Gross profit | $170.88M | $179.81M | $162.34M | $152.74M | $143.26M | $140.67M |
| R&D | $69.38M | $54.96M | $50.16M | $34.54M | $25.39M | $63.58M |
Harmony Biosciences Holdings, Inc. reported annual revenue of $868.45M for fiscal year 2025. That is up 21.5% from $714.73M in fiscal 2024. Over the 7 fiscal years shown, annual revenue grew from $6.00M (FY 2019) to $868.45M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A | $32.51M | $29.81M | $33.92M | $31.24M | $28.59M | $27.22M |
| Operating income | $37.29M | $65.49M | $48.18M | $56.24M | $61.71M | $21.36M |
| Income tax | $7.20M | $16.63M | $9.86M | $11.62M | $16.08M | $10.10M |
| Net income | $32.49M | $50.87M | $39.78M | $45.56M | $46.09M | $11.59M |
| EPS (diluted) | $0.55 | $0.87 | $0.68 | $0.78 | $0.79 | $0.20 |